A therapeutic antibody candidate (AT-19) isolated using multivalent phage display binds native tomoregulin (TR) as a multimer not as a monomer. This report raises the importance of screening and selecting phage antibodies on native antigen and reemphasizes the possibility that potentially valuable antibodies are discarded when a monomeric phage display system is used for screening. A detailed live cell panning selection and screening method to isolate multivalently active antibodies is described. AT-19 is a fully human antibody recognizing the cell surface protein TR, a proposed prostate cancer target for therapeutic antibody internalization. AT-19 was isolated from a multivalent single-chain variable fragment (scFv) antibody library rescued with hyperphage. The required multivalency for isolation of AT-19 is supported by fluorescence activated cell sorting data demonstrating binding of the multivalent AT-19 phage particles at high phage concentrations and failure of monovalent particles to bind. Pure monomeric scFv AT-19 does not bind native receptor on cells, whereas dimeric scFv or immunoglobulin G binds with nanomolar affinity. The isolation of AT-19 antibody with obligate bivalent binding activity to native TR is attributed to the use of a multivalent display of scFv on phage and the method for selecting and screening by alternate use of 2 recombinant cell lines. (Journal of Biomolecular Screening 2006:985-995) 
INTRODUCTION
P HAGE DISPLAY TECHNOLOGY is a powerful in vitro method to generate fully human antibodies to self-proteins by mimicking the body's immune repertoire. This flexible technology produces various outcomes depending on the antibody phage library used, the mode of display on the phage particle, the selection or panning method, and the screening technique used to identify valuable clones. These methods are explored here to find a selective, high-affinity antibody internalized by tomoregulin (TR), a therapeutic target in prostate cancer. 1 Different modes of display on filamentous phage and different methods to rescue phagemid libraries have been described. 2, 3 The valency of display for proteins on the M13 phage can range from one to thousands depending on the display site and vector used. Monovalent antibody display is a popular display mode thought to enhance discrimination between moderate-and highaffinity clones by eliminating the effect of avidity that contributes to multivalent binding. 4 However, several recent reports highlight the value of a multivalent display for cell-surface selections especially when antibodies with rare biologic properties are desired. [5] [6] [7] [8] Antibody fragments are most commonly fused to the gene III protein and displayed either by cloning the antibody gene directly into the phage genome (Fd phage library) or cloning into gene III expressed on a phagemid plasmid. The latter system used here requires rescue with a helper virus to generate particles displaying the gene III protein fused to the single-chain variable fragment (scFv) antibody. Performance of the gene III display/ helper virus system is enhanced by elimination of deficiencies including the low frequency of antibody display and the propagation of insertless phage. [9] [10] [11] [12] These improvements were incorporated by employing a helper virus called hyperphage to generate a multivalent library. Multivalency occurs due to the absence of gene III from this helper virus. All gene III fusion proteins (∼5 per phagemid) are derived from the phagemid and undiluted by wild-type gene III protein. 9, 13 Hyperphage rescued phagemid improves selections by decreasing off rates, increasing avidity, increasing the fraction of particles displaying scFv, and reducing amplification of phage lacking inserts. A multivalent display was chosen because the desired final format is a bivalent therapeutic immunoglobulin G (IgG).
In conventional applications, phage display antibodies are selected against purified recombinant antigen immobilized on an immunotube, enzyme-linked immunosorbent assay (ELISA) plate, or bead. 3, 14 However, therapeutic antibodies function by binding the native receptor conformation on the surface of live cells in vivo. Some membrane protein antigens require their native environment to maintain a functional 3-dimensional structure. Cell surface panning is an attractive alternative to discover specific antibodies to native antigens when soluble recombinant antigen is unavailable or when recombinant protein shows poor immunogenicity. [15] [16] [17] [18] [19] [20] [21] The cell surface is a rich source of both target and nontarget proteins; therefore, both specific and nonspecific phage antibodies propagate during selections from naïve phage libraries. [22] [23] [24] [25] [26] [27] Counterselection at each round improves enrichment factors and depletes nonspecific phage by preadsorbing the library on cells that do not express the target antigen. Of greater importance for enrichment of specific phage antibodies is the use of cells that overexpress the target antigen to levels of ∼10 6 or more per cell. Counterselection of the phage library on negative cells was coupled with alternating the positive cell line at each round of panning. Two different recombinant cell lines were generated, 1 in Chinese hamster ovary cells (CHO-K1) and 1 in human prostate cancer cells (PC-3). By alternating hamster and human recombinant cell lines at each round, the amplification of nonspecific phage antibodies is diminished because these cell lines do not express the same set of nontarget proteins. Finally, the sensitivity of the primary screening assay was amplified using the previously described immune complex ELISA (ICELISA). 28, 29 Dimerization of the scFv following capture with an antitag monoclonal antibody increases the avidity for difficult epitopes allowing discovery of antibodies with fast monomeric off rates.
In vivo studies demonstrate that TR is a promising target for both radioimmunotherapy 1 and antibody-drug conjugate immunotherapy. 30 Antibody internalization is key for the latter approach, as exemplified by Mylotarg (gemtuzumab ozogamicin), a therapeutic antibody conjugated to the toxin calicheamicin and internalized by CD33. 31 The high-affinity, TR-specific, internalizing human antibody AT-19 was isolated from a human, naïve antibody phage display library by a combination of alternating panning and screening methods. The tools and methods used include a multivalent human scFv phage display library, the creation of 2 TR overexpressing recombinant cell lines, and the development of a screening assay capable of identifying an antibody that preferentially binds in the bivalent format.
MATERIALS AND METHODS

Recombinant TR protein production
The extracellular domain of TR comprising amino acids 1 to 302 was expressed and secreted with a baculovirus system. The cDNA encoding the extracellular domain was amplified with primers encoding an N-terminal-optimized Kozak sequence and a C-terminal 6x-His tag preceded by 2 glycine residues and followed by a stop codon. The PCR product was digested with restriction enzymes BamHI and KpnI and cloned downstream of the polyhedrin promoter into the baculovirus transfer vector pBBS250. Recombinant baculovirus was produced by cotransfection with BaculoGold™ DNA (BD Biosciences, San Diego, CA) and subsequent plaque isolation. High Five™ cells were infected at a multiplicity of infection (MOI) of 3, and the cell culture supernatant was harvested after 72 h. The protein was purified in a 2-step procedure by Ni 2+ chelating and size exclusion chromatography. The protein exhibits correct processing of the signal sequence after amino acid Ala 40 and is glycosylated.
Reagents
Mab 2H8 is a murine IgG1 monoclonal antibody that reacts with the follistatin domains of the extracellular region of human TR protein. The antibody was recently described. 1, 35 It is used throughout as a positive control antibody.
Cell line generation
The human prostate carcinoma cell line PC-3 and the Chinese hamster ovary cell line CHO-K1 were purchased from American Type Culture Collection (ATCC, Manassas, VA). PC-3 cells were grown in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin, at 37°C in a humidified atmosphere of 5% CO 2 . CHO-K1 cells were maintained in ATCC complete growth medium (Ham's F12 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 90%; FBS, 10%). Stable transfection of PC-3 or CHO-K1 cells with the expression vector pcDNA3.1-TR generated the PC-3-TR and CHO-TR cell lines, respectively. These cells were maintained in growth medium, supplemented with 400 µg/mL G418. Cells were characterized by flow cytometry and internalization assay. Based on Scatchard analysis, PC-3-TR cells express 0.65 million TR molecules per cell and CHO-TR are estimated by FACS analysis to express 1.8 million TR molecules per cell.
scFv library generation
The scFv library generation was based on published reports. 32, 33 The variable genes (V H , V κ , and V λ ) were PCR cloned from pooled mRNA from human bone marrow, lymph node, and spleen using a set of family-specific primers and a minimal number of PCR cycles. The resultant pCITE-VH (3.9 × 10 9 members), pZ604-V κ (1.6 × 10 7 ), and pZ604-V λ (3.2 × 10 7 ) libraries represent a permanent and high-diversity source of V genes. The V H genes were PCR amplified from the pCITE-V H library, and the V κ and V λ genes were PCR amplified from the pZ604-V κ and pZ604-V λ library together with the reverse J H and linker sequence at the 5′ end. The gel-purified V H -, V κ -, and V λ -containing PCR products were then spliced together by overlap extension PCR to make the scFv gene repertoire. The scFv gene repertoire was cloned into a phagemid vector pZ603, and the ligation product was electroporated into competent TG1 Escherichia coli cells to generate the scFv phage display library, HuPhabL3, with 5.2 × 10 9 individual transformants. Pz603 is based on the commercially available pCANTAB5E (Amersham GE Healthcare, Piscataway, NJ) with an NcoI site introduced 5′ to the V H region. A high diversity as indicated by the library size of 5.2 × 10 9 along with 94% insert frequency indicates a highquality library (data not shown). The library was rescued with hyperphage (Research Diagnostics Inc., Concord, MA) at an MOI of 20; phage was precipitated by polyethyleneglycol (PEG)/NaCl and purified by standard methods. The hyperphage-rescued library was used as the input for the 1st round of panning.
Differential cell panning strategy
Three rounds of panning with the multivalent, hyperphage rescued library were designed 1) to alternate the cell line used to present the TR antigen and 2) to preabsorb nonspecific phage on TR-negative cells. In round 1, CHO-K1 parental cells (1 × 10 8 ) were blocked with 10 mL blocking buffer (2% bovine serum albumin [BSA], 10% FBS in phosphate buffered saline [PBS]) for 1 h at 4°C. The cells were divided into 3 tubes and pelleted at 1000 rpm for 5 min. The multivalent scFv phage display library, diluted in 5 mL blocking buffer, was incubated sequentially for 30 min with each tube of parental cells at 4°C while rocking. After the 3rd depletion step on the CHO-K1 parental cells, the library (supernatant) was added to CHO-TR cells (1 × 10 7 ) for selection on the positive cell line for 2 h at 4°C with rocking. The cells were then washed 10 times with 10 mL blocking buffer, changing tubes with each wash. Phage that remained bound was eluted by lysing the cells with 0.5 mL of 100 mM triethylamine for 10 min followed by neutralization with 1 mL of 1 M Tris buffer, pH 7.5. In round 2, the same procedure as described for round 1 was used, except 15 washes were performed after selection on the positive cell line. PC-3 parental cells and PC-3-TR-positive cells were used instead of CHO-K1 and CHO-TR cells. In round 3, the same procedure as described for round 1 was used, except 20 washes were performed after selection on the positive (CHO-TR) cell line. Phage amplification and purification were performed by standard methods. 34 Briefly, eluted phage from each round was amplified by infection of 15 mL log phase TG1 E. coli with 0.75 mL of eluate. TG1 were grown at 37°C to an OD 600 of 0.7 at 37°C. After addition of the eluate, TG1 were incubated at 37°C for 30 min, then 0.1, 1, and 10 µL of the culture was plated onto 10-cm agar plates to determine phage titers indicating the number of phage particles in the eluate or phage stock. The bacterial cells were then pelleted by centrifugation at 3000 rpm, the supernatant was removed, and the cell pellet was spread onto two 15-cm agar plates with 2XTY, carbenicillin (100 µg/mL), 1% glucose. The plates were incubated at 37°C overnight. Glycerol stocks of the bacteria were prepared by scraping the colonies off the plates using a total of 4 mL of 2XTY, carbenicillin (100 µg/mL), 1% glucose, 17% glycerol, and they were stored at -80°C. For rounds 1 and 2, 13 mL of 2XTY, carbenicillin (100 µg/mL), 1% glucose, was inoculated with an aliquot of the glycerol stock, bringing the starting OD 600 to approximately 0.05. The culture was grown to log phase at 37°C, infected with hyperphage (Research Diagnostics Inc, Concord, MA) at an MOI of 20, and then incubated for two 45min periods at 37°C, first stationary and then with agitation. The culture was centrifuged at 3000 rpm to pellet the bacteria, the supernatant was removed, and the bacterial pellet was resuspended in 50 mL 2XTY, carbenicillin (100 µg/mL), kanamycin (50 µg/mL). The culture was grown overnight at 28°C. Phage was purified from the overnight culture by standard methods using PEG precipitation.
Primary screening by reverse-capture ICELISA and differential cell-based ELISA
Single colonies from the 3rd round of panning were picked into 96-well plates, and plates expressing soluble scFv formatted as single clones were prepared for screening. ScFv were expressed by growth of clones to log phase under selection in carbenicillin followed by induction with 1 mM isopropyl-b-D-galactopyranoside (IPTG). After induction, plates were grown overnight at 28°C using a GeneMachines HiGro high-capacity incubator (Genomic Solutions, Ann Arbor, MI) in an O 2 atmosphere with shaking at 500 rpm. The next day, plates were spun at 3000 rpm to pellet bacteria, and the supernatant was used for screening by an ICELISA adapted from the method described by Amersham GE Healthcare for the recombinant phage display antibody system (RPAS). Screening was performed on 6xHis-tagged recombinant TR expressed in insect cells as described above. Anti-Etag-antibody (Amersham GE Healthcare, Piscataway, NJ) was coated onto the ELISA plate overnight at 4°C at a concentration of 1 µg/mL. The ELISA plate was then blocked with 5% dry milk/PBS for an hour and then washed once. A total of 100 µL of bacterial cell culture supernatant was transferred from the expression plate to the ELISA plate to capture the antibody. ELISA plates were incubated for 1 h at room temperature. Plates were washed 3 times in 0.05% Tween PBS. Recombinant TR Selection of a High-Avidity Antibody to Tomoregulin (100 µL, 2 mg/mL) was added for 1 h at room temperature followed by 3 washes. TR was probed with anti-6xHis-HRP (horse radish peroxidase). After 3 final washes, the plate was developed with Amplex Red reagent (Invitrogen, Carlsbad, CA) and read at Ex 530 /Em 590 on a Gemini EM fluorometer (Molecular Devices, Sunnyvale, CA). Differential cell ELISA screening was performed on CHO-TR and on CHO-K1 cells grown adherently to confluence on collagen I 96-well cell culture plates (BD Biocoat, BD Biosciences, San Diego, CA). A total of 100 µL of bacterial cell culture supernatant from the expression plate was then transferred to the cell ELISA plate. ELISA plates were incubated for 1 h at 4°C. The plates were washed 3 times with cold PBS containing calcium and magnesium (GIBCO Invitrogen, Carlsbad, CA). Anti-Etag-HRP (Amersham GE Healthcare, Piscataway, NJ) diluted in blocking buffer to a final dilution of 1:5000 was added for 1 h at 4°C followed by 3 washes in cold PBS. The ELISA plate was developed with Amplex Red HRP substrate and read in the fluorometric plate reader (Ex 530 /Em 590 ).
Characterization of AT-19 binding by monovalent or mulitvalent phage particles
TG1 cultures of AT-19 scFv were grown and rescued with helperphage and hyperphage at an MOI of 20 using phage prepared as described above. Phage samples were labeled directly with Alexa-488 by using the Alexafluor488 proteinlabeling kit (Invitrogen). Concentrated phage samples (5 × 10 13 phage/mL) were incubated for 1 h with the labeling reagent at room temperature. The labeled phage was then separated from the free reagent by gel filtration on a Sephadex-10 column. The eluted phage was PEG precipitated twice, washed twice with PBS, and resuspended in 0.5 mL PBS. Titers of the purified phage samples were established by ELISA. A standard curve was generated using phage of known concentration serially diluted in an ELISA plate and incubated overnight at 4°C. The unknown phage samples were also diluted 10-fold and incubated in the ELISA plate overnight at 4° C. The ELISA plate was washed with 0.05% Tween PBS 3 times and then incubated with anti-M13-HRP for 30 min at room temperature. This was followed by 3 washes, and then the plate was developed with Amplex Red fluorescent developing reagent (Invitrogen). The plate was read on a fluorescence plate reader (Ex 530 /Em 590 ). The phage concentrations of the unknown samples were determined from the fluorescence of the standard curve. Fluorescence-activated cell sorting (FACS) analysis of the monovalent and multivalent AT-19 phage particles was performed on CHO and CHO-TR cells. The cells were grown to confluence in F12 media supplemented with 10% FBS. CHO-TR cells were grown under G418 selection. Cells were detached with Cell Dissociation Buffer (GIBCO Invitrogen) and collected by centrifugation (1000 rpm, 4°C, 5 min). A total of 2 × 10 5 cells in 100 µL PBS buffer were incubated for 1 h at 4°C with AT-19 anti-TR phage antibodies at a range of concentrations. Excess antibody was removed by washing 3 times with 1 mL PBS followed by centrifugation.
scFv expression and purification
HB2151 E. coli cells transfected with the scFv gene were grown in 1 L of media to log phase (OD 600 = 0.7), induced with 0.75 mM IPTG, and grown overnight at 28°C. The scFv was extracted from the periplasm using bacterial protein extraction reagent (B-PER, Pierce Biotechnology, Rockford, IL). The scFv was purified from the sterile-filtered supernatant using the RPAS purification module (Amersham GE Healthcare), which relies on anti-Etag affinity chromatography. Samples were prepared in NuPAGE sample buffer and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis using 4% to 12% precast Bis-Tris gels in NuPAGE MES running buffer (Invitrogen, Carlsbad, CA). The protein concentration was determined by the method of Bradford using reagents from Pierce Biotechnology.
Format switching: from scFv to IgG
The cDNA encoding the variable regions (V L and V H ) of antibody AT-19 were first fused by a PCR method to the IgG 1 signal sequence of the expression vector pIE_SRγ1fa (Medarex Inc, Milpitas, CA) encoding the C H and C L kappa chains of human IgG 1 . The V L and V H were in frame with the respective C L and C H regions in the final construct (pIE/TR_Ab). HEK 293 EBNA cells were transfected in suspension with pIE/TR_Ab and conditioned media harvested 3 days posttransfection for purification.
AT-19 IgG purification
Conditioned medium from HEK 293 EBNA cells was centrifuged (5000g, 20 min), loaded on a 5-mL Poros Protein A column (Applied Biosystems, Foster City, CA), and equilibrated with 50 mM sodium acetate, 150 mM NaCl, pH 6.5, using an AKTA system (Amersham GE Healthcare, Upsala, Sweden). The antibody containing eluant was collected in a pool corresponding to the increase in OD 280 following gradient elution to 50 mM sodium acetate, 150 mM NaCl, pH 3, over 5 min, and immediately, the pH of the pool was raised to pH 5 using 1 M sodium hydroxide. A total of 1.9 mg of antibody was recovered per liter of conditioned media and analyzed as described above for the scFv.
AT-19 antibody characterization
Purified AT-19 antibodies (scFv or IgG) were characterized by ELISA and ICELISA on recombinant protein (direct) and on adherent cells expressing TR. AT-19 IgG was also characterized by FACS. Cell ELISA and ICELISA were performed at 4°C. Plates were blocked for an hour in blocking buffer (5% lowfat skim milk powder/PBS for direct assays, HAM's F12 media [GIBCO Invitrogen] for cell assays) prior to the addition of the primary antibodies. For ELISA assays, the AT-19 scFv was prepared at the desired concentrations in 2% BSA. A total of 100 µL was transferred to the ELISA plate, incubated for 1 h, and then washed 3 times with wash buffer (0.05% Tween PBS for both the ELISA and ICELISA on recombinant protein, or cold PBS with Ca 2+ and Mg 2+ for both the cell ELISA or cell ICELISA). The secondary antibody (mouse anti-Etag HRP, 1:5000) was then added for 30 min followed by 3 washes in wash buffer. The plates were then developed with 50 µL per well Amplex Red reagent as described above. For ICELISA assays, AT-19 scFv was prepared at the desired concentration in 2% BSA with 1:5000 anti-Etag HRP and incubated on ice for 1 h. A total of 100 µL was then transferred to the ELISA plate, incubated for 1 h, washed 3 times in washing buffer (as above), and then developed with 50 µL per well Amplex Red reagent. For ELISA with IgG, antibodies were prepared at the desired concentration in 2% BSA. A total of 100 µL was transferred to the ELISA plate, incubated for 1 h, and washed 3 times in washing buffer, and 100 µL of either rabbit anti-human-IgG antibody-HRP for AT-19 IgG or rabbit anti-mouse-IgG antibody-HRP for Mab 2H8 (both 1:1000 in 2% BSA; Sigma, St. Louis, MO) was then added for 30 min, followed by 3 washes with washing buffer. The plates were then developed with 50 µL per well Amplex Red reagent.
Flow cytometry (FACS) of anti-TR IgG on TR-expressing cells
Cells were detached with Cell Dissociation Buffer (GIBCO Invitrogen) and collected by centrifugation (1000 rpm, 4°C, 5 min). Then, 2 × 10 5 cells in 100 µL PBS buffer were incubated for 1 h at 4°C with anti-TR antibodies at a range of concentrations. Excess antibody was removed by washing with 1 mL PBS followed by centrifugation. Cells were resuspended and incubated for 45 min at 4°C in 100 µL PBS containing the secondary antibody, either anti-human IgG-fluorescein isothiocyanate (FITC) for AT-19 IgG or anti-mouse IgG-FITC for Mab 2H8 (both 10 µg/mL; Vector Labs Inc., Burlingame, CA). Excess antibody was washed away with 1 mL PBS followed by centrifugation. Cells were resuspended in 200 µL PBS containing 5 µL propidium iodide (1 µg/mL). Fluorescence intensity was measured on a FACS Calibur (Becton Dickinson, Franklin Lakes, NJ). Experiments were performed in triplicate.
Internalization assays and confocal microscopy
Cells were grown in RPMI-1640 medium (GIBCO Invitrogen) with 10% FBS on 8-well glass chamber-slides (Nalgene Nunc International, Naperville, IL) overnight. The next day, growth medium was replaced with medium containing primary antibody AT-19 IgG (2 µg/well) at 4°C for 2 h. Cells were washed 3 times with cold PBS. The secondary antibody, AlexaFluor-488 goat antihuman IgG (H + L) antibody (Invitrogen), was then added at a dilution of 1:500 and incubated at 4°C or 37°C for 3 h followed by 3 washes in cold PBS. Plasma membranes were counterstained with Wheat Germ Agglutinin-Alexa Fluor 594 Conjugate (Invitrogen). Cells were washed 3 times with PBS, fixed using 5% paraformaldehyde in PBS for 10 min at room temperature, and washed 2 additional times using PBS. Slides were coverslipped using Fluorescent Mounting Medium (DakoCytomation, Carpinteria, CA). Confocal images of the double-labeled cells were captured using an LSM5 Pascal confocal laser scanning microscope (Carl Zeiss AG, Jena, Germany) equipped with a PlanNeofluar 63x/1.25 oil objective (Carl Zeiss AG). Slides were scanned using the multitrack mode (red and green channel) to avoid bleed through. Images represent a stack of 20 focal planes (1 µm apart). Single frames from representative stacks were exported into Adobe Photoshop 7.0 and saved as jpeg files.
RESULTS
Panning success revealed by increased titers of eluted phage and insert frequency
Three rounds of panning were completed using the multivalent scFv phage display library. Comparison of the phage titers of the input, the last wash before phage elution, and the eluted phage from each round of panning indicates a successful panning strategy ( Table 1 ). The input titer for round 1 is the phage concentration of the library itself, and the input titers for rounds 2 and 3 are the titers of the amplified phage eluted from the previous round of panning. The elution titers represent phage eluted from the cell surface after several wash steps and before amplification. The increasing titers of eluted phage, by at least 1 log per round of panning, indicate that the selection strategy amplified specific clones at each round of selection. Comparison of the titers of the eluted phage with the titers of the last wash indicates that the eluted phage is specific for the target TR because increasingly stringent washing steps resulted in substantially lower titers in the last wash versus the eluted phage. Finally, the insert frequency in the 3rd round of panning was evaluated by a restriction digest (NcoI-NotI) of 20 random clones, and 100% of clones were shown to contain the scFv insert by this method (data not shown). Thus, nonbinding, insertless phage were not enriched during the panning and stringent washing steps, again indicating a successful selection strategy.
Primary screening and sequence analysis of polyclonal scFv from round 3
A total of 616 single clones from the 3rd-round phage antibody pool were screened by the reverse-capture ICELISA and by differential live cell ELISA. The primary screen yielded 19 positive wells in common for both assays. All 19 clones gave a single sequence (available on request) and designated AT-19.
Influence of valency on the binding of AT-19 phage, scFv, and IgG
AT-19 monovalent and multivalent phage particles were prepared, fluorescently labeled, and tested by FACS on CHO and CHO-TR cells. The results show that binding is clearly dependent on the valency of the phage particles (Fig. 1) . The multivalent phage particles specifically bind TR-expressing cells throughout the entire concentration range, but the equivalent high-concentration range of monovalent phage particles binds poorly to CHO-TR. Binding is similar to control CHO cells, even at the highest concentration tested (5 × 10 13 phage/mL). Thus, monomeric AT-19 phage antibody particles do not bind to TR-expressing cells.
The role of valency was further investigated using purifed scFv and IgG proteins. The pure monovalent AT-19 scFv was tested for binding to native TR on cells in a cell-based ELISA at concentrations of 5 µg/mL (200 nM), 1 µg/mL (40 nM), and 0.2 µg/mL (8 nM). Binding of monomeric AT-19 scFv was negligible and similar to the binding of nonspecific scFv controls, in contrast to the robust binding by Mab 2H8 (Fig. 2A, left) . A different result was found when the AT-19 scFv monomer was dimerized by preincubation with anti-Etag-HRP mouse IgG prior to incubation with cells in an ICELISA. Robust binding to the native TR receptor was observed for the immune complex of both crude and pure AT-19 scFv compared to dimerized scFv control ( Fig. 2A, right) . The concentration dependence of the dimerization of AT-19 scFv in the live-cell ICELISA yields an EC 50 of ∼8.5 nM for binding to the native receptor ( Fig. 2B) and is based on the total concentration of AT-19 scFv in each dilution. The exact concentration of the desired ternary complex of (scFv) 2 /IgG is not known under the conditions of this assay because both the concentration of secondary IgG and the binding affinity to the peptide tag on the scFv are unknown.
Under the experimental conditions used for Figures 2A and  2B , the apparent binding of the immune complex in the livecell ICELISA decreases at higher concentrations of scFv, tending toward a bell-shaped curve. This is likely because of the use of a single dilution (1:5000) of the mouse anti-Etag HRP secondary antibody with all dilutions of the scFv. At a fixed concentration of secondary antibody, the ratio of total scFv to anti-Etag IgG increases at higher concentrations of scFv. The binding sites on the secondary antibody are saturated at high concentrations of scFv, leading to an increasing concentration of unbound scFv as the concentration of total scFv increases. The excess free scFv will compete for binding with the immune complex or allow only monovalent binding of the immune complex during the binding phase of the assay. Following the subsequent wash steps, a lower amount of immune complex will remain bound compared to concentrations of scFv with a lower ratio of free scFv to immune complex. Finally, although bivalent immune complex formation improves binding of the monovalent scFv format, immune complex formation decreases binding at all concentrations of the IgG Mab 2H8. Comparison of the performance of Mab 2H8 in the ELISA ( Fig. 2A, left) versus the ICELISA ( Fig. 2A, right) demonstrates that dimerization of the bivalent Mab 2H8 IgG in an immune complex is actually detrimental to binding. The very high molecular weight of this immune complex that contains 3 IgG molecules (1 rabbit IgG and 2 Mab 2H8) likely results in poor access to the TR epitope due to steric constraints.
In a direct ELISA, AT-19 scFv appears to bind as a monomer to the recombinant protein attached to the plastic well, although significantly weaker than the dimeric immune complex in the ICELISA (Fig. 3) . AT-19 scFv exhibits an EC 50 of 22 nM in the direct ELISA, whereas dimerization of AT-19 in the ICELISA improves this EC 50 at least 15-fold to ∼1.4 nM, demonstrating a substantial avidity effect even to the immobilized soluble recombinant protein.
Finally, when AT-19 is converted to the fully human IgG, the full avidity effect is observed (Fig. 4) . Titration of the dimeric antibody format of AT-19 IgG in a live-cell ELISA binding to PC-3-TR cells yields an EC 50 of 0.44 nM. Binding of AT-19 IgG to PC-3-TR cells was further tested in a FACS assay ( Fig. 5A) and The scFvs and secondary antibody were added sequentially for the ELISA. In contrast, in the live-cell ICELISA, specific binding to the native TR on PC-3-TR cells is readily demonstrated by AT-19 scFv after dimerization (right). In the ICELISA, scFv was preincubated with mouse anti-Etag monoclonal immunoglobulin G (IgG) to form an immune complex composed of the anti-Etag IgG molecule bound to 2 scFvs. Nonspecific binding by the immune complex of control scFv is low. Mab 2H8 is a positive control anti-TR mouse IgG that binds strongly in the ELISA but poorly as the immune complex. It is likely that the very high molecular weight of this immune complex containing 3 IgG molecules (1 rabbit IgG and 2 Mab 2H8) results in poor access to the TR epitope due to steric constraints. The mean of triplicate assays ± SD. (B) Concentration dependence of AT-19 scFv immune complex binding to native TR in the live-cell ICELISA. AT-19 scFv was complexed with the secondary mouse anti-Etag monoclonal antibody before addition to cells. The EC 50 of ∼8.5 nM is based on the total concentration of scFv and is an underestimate of the potency of the dimer because the concentration of the immune complex is not known. All dilutions are in triplicate. Biacore. 1 The observed EC 50 for AT-19 IgG was 0.17 nM. Neither AT-19 nor Mab 2H8 bind control parental PC-3 cells by FACS analysis (data not shown). No detectable binding of the scFv monomer was observed by FACS even at concentrations as high as 2 µg/mL (80 nM, data not shown). In contrast to the direct ELISA, the live-cell FACS (Fig. 5 ) and live-cell ELISA ( Fig. 2A and Fig. 4 ) analyses indicate that the AT-19 antibody exhibits an avidity effect when binding to the native receptor in the range of 100-to 500-fold.
Internalization of AT-19 IgG by TR-expressing cells
AT-19 IgG is shown to bind specifically to TR-expressing cells by immunofluorescence. No fluorescent staining is observed for TR-negative CHO-K1 cells at either 4°C (Fig. 6A) or 37°C (Fig. 6C) , indicating that binding and subsequent internalization is specifically mediated by TR and not off-target interactions with FcRs or other molecules. Figures 6B and 6D are the corresponding phase contrast images indicating the presence of TR-negative cells in the frame. At 4°C, AT-19 IgG is present only on the surface of the TR-positive cells (Fig. 6E) . Incubation of TR-positive cells at 37°C with AT-19 results in internalization of the Alexa 488-labeled AT-19 surface protein into vesicular cytoplasmic structures (Fig. 6F) . The plasma membrane is visualized with WGA-Alexa594 (red).
DISCUSSION
An antibody to the prostate cancer cell surface marker, TR, was discovered by a combination of 3 nonconventional approaches in phage display technology. First, a multivalent scFv phage display library was generated by rescuing the stock phagemid library and each round of panning with hyperphage. Second, alternating cell surface selections were employed with cell lines derived from 2 species (hamster and human) including preadsorption with appropriate control cells (counter selection) at each round of panning. Third, scFv was screened using a capture ICELISA allowing multivalent antibody binding. Without the combination of these specific methods, the unique antibody, AT-19, could not have been isolated. Combination of these methods is a useful alternative to generate therapeutic antibodies to difficult antigens.
The identification of antibodies to TR using phage display is highly sensitive to the method of antigen presentation. Prior to this study, selections were performed using a monovalent phagemid library rescued with conventional helperphage. Selections were performed both with recombinant antigen and by cell surface panning on PC-3-TR cells (0.65 × 10 6 receptors/cell). These are standard selection approaches, [36] [37] [38] but neither yielded antibodies recognizing native TR on cells. Antibodies identified with recombinant TR bound recombinant antigen but not native-form TR expressed on cells. Cell panning found only non-TR-binding clones specific to the parental PC-3 cell line (unpublished data). Difficulties with cell-surface panning have been described 27 and may be attributed to insufficient expression levels of the target antigen or inadequacy of the counterselection on parental cells. The use of helperphage may also have contributed to the lack of success. Helperphage rescue yields a library with a low level of antibody display, and propagation of insertless phage occurs because helperphage encodes a normal gene III protein.
To address these issues, the original monovalent phagemid library was rescued with hyperphage creating a multivalent library, and an improved cell-surface panning strategy was developed. Increased selection efficiency of phage display technology using multivalent antibody presentation is attributed to increased display frequency and avidity effects. 6, 7, 9 Hyperphage also reduced the occurrence of insertless phage. After 3 panning rounds with hyperphage rescue, all clones had scFv inserts in DNA isolated from a panel of randomly picked clones. The titers of eluted phage increased ∼10-fold each round, indicating strong selective pressure ( Table 1) .
To enrich for specific phage, a selection strategy was developed using 2 TR-positive cell lines with different background matrices. A new recombinant cell line (CHO-TR) was created with expression levels of 1.8 × 10 6 receptors per cell and was used in combination with the human PC-3-TR cell line (0.65 × 10 6 receptors per cell). The background matrix surrounding the TR antigen is different for each cell line because one is derived from a hamster cell line (CHO-K1) and the other from human (PC-3). These cell lines were alternately panned during 3 rounds (CHO-TR, PC-3-TR, CHO-TR) to avoid matrix-binding clones (non-TR-binding clones). Preadsorption of the library on parental cells at each round of panning (CHO, PC-3, CHO) further depleted the library of nonspecific antibodies.
To increase the number of TR-binding clones selected from the polyclonal scFv pool after round 3, a multivalent reversecapture ICELISA was developed as the primary screen. The Etag-labeled scFv was captured directly from bacterial cultures on anti-Etag IgG ELISA plates to create a surface of bivalent scFv immune complexes to assay. Next, 6x-His-tagged recombinant TR protein is bound, and then TR is detected with anti-6x-His-HRP antibody conjugate. Even weakly binding scFv is captured because of avidity effects. A total of 19 hits were found after screening 616 phage from round 3 (3%), and all 19 had the sequence of AT-19. Isolation of a single unique clone may reflect the limited number of clones in the library that recognize native TR on cells or may result from the high stringency of the panning method employed. This approach of high stringency and multiple wash steps is used to eliminate nonspecific phage. 25, 26 Although panning may be optimized with fewer washes, 22, 24, 27 it is noteworthy that no nonspecific clones were found when the round 3 clones were screened on parental PC-3 cells. The efficient panning strategy described here alternately uses 2 TR-positive cell lines with their respective parental cell lines to completely remove nonspecific binders.
Characterization of AT-19 suggests that this antibody could have been isolated only using a multivalent phage display library and cell surface panning. It may have been lost if the ICELISA were not employed for its detection. AT-19 requires multivalency to bind TR and does not bind native TR protein as a monomer. When monovalent AT-19 phage particles are tested by FACS on TR-expressing cells, they do not bind even at high phage concentrations. Multivalent AT-19 phage particles bind specifically to TR-expressing cells (Fig. 1) , and the pure scFv form of AT-19 binds as the bivalent immune complex (Fig. 2) . Pure monovalent scFv fails to bind native receptor on cells even at concentrations up to 200 nM ( Fig. 2A) . The full avidity effect is observed when the IgG form of AT-19 is compared to the scFv ( Fig. 2A) . AT-19 IgG exhibits an EC 50 of 0.44 nM by cell ELISA and 0.17 nM by FACS ( Fig. 4 and Fig. 5A ). For comparison, the mouse anti-TR Mab 2H8 was tested and found to have an affinity of 0.67 nM, similar to the value of 1 nM determined by Biacore. 1 The multivalent phage particle by hyperphage rescue plays a similar role as both the anti-Etag IgG in the immune complex or the constant region of the IgG. All 3 present at least 2 copies of AT-19 to the antigen. The immune complex and the multivalent phage present 2 or more scFv, whereas the IgG presents a V H and V L on both arms of the bivalent antibody. Multivalent phage display may be a prerequisite for the isolation of antibodies that dissociate rapidly when bound as monomers. In the absence of the multivalent avidity increase, phage antibodies such as AT-19 are lost in the wash steps designed to eliminate nonbinding phage. AT-19 is a valuable antibody with therapeutic potential that would have been lost using a conventional panning approach. The potential for AT-19 IgG to deliver toxin for cancer immunotherapy is shown by its selective internalization into TR-expressing cells (Fig. 6) .
It is not possible to quantify the amount of influence contributed by each of the individual features of this unique selection strategy because a systematic series of panning studies has not been performed. However, the full characterization of AT-19 in the scFv, the IgG, and the phage-antibody formats by a combination of ELISA, ICELISA, and FACS supports the assertion that the multivalent library, the dual alternating cell surface selection, and the ICELISA primary screening method all contributed to the isolation of AT-19. It is likely that had any one of these features been omitted, the AT-19 antibody would not have been isolated. AT-19 is the first reported fully human, internalizing IgG to TR.
